The ending of my career is unknown.
I'm not a smart person, however, I can learn quickly and always do my best.
“We live and learn, or, perhaps more importantly we learn and live.”
— Terry Pratchett
My published collaborative research, to date. Just a few work inside.
Wei Nie, Mi-Die Xu, Lu Gan, Yi Zhang, Jie Qian, Kai Gu, Xue-Yan Zhang,... & Bao-Hui Han (2019) Advanced Non-Small Cell Lung Cancer Patients With Low Tumor Mutation Burden Might Derive Benefit From Immunotherapy, J Immunother 43(6):189-195 [PMID: 32209830]
Wei Nie, Jie Qian, Mi-Die Xu, Kai Gu, Fang-Fei Qian,... & Bao-Hui Han (2020) Prognostic and Predictive Value of Blood Tumor Mutational Burden in Patients With Lung Cancer Treated With Docetaxel, JNCCN 18(5):582-589 [PMID: 32380463]
Wei Nie, Jie Qian, Mi-Die Xu, Kai Gu, Fang-Fei Qian,... & Bao-Hui Han (2020) A non-linear association between blood tumor mutation burden and prognosis in NSCLC patients receiving atezolizumab, Oncoimmunology 9(1):1731072 [PMID: 32158623]
Wei Nie, Lu Gan, Xin Wang, Kai Gu, Fang-Fei Qian,... &Bao-Hui Han (2021) Atezolizumab prolongs overall survival over docetaxel in advanced non-small-cell lung cancer patients harboring STK11 or KEAP1 mutation, Oncoimmunology 10(1):1865670 [PMID: 33537171]
Shixiang Wang, Yi Xiong, Kai Gu, Longfei Zhao, Yin Lia, Fei Zhao, Xuejun Li, Xue-Song Liu (2021) UCSCXenaShiny: an R package for exploring and analyzing UCSC Xena public datasets in web browser, Bioinformatics. [PMID: 34323947] DOI: 10.1093/bioinformatics/btab561
Anning Xiong, Wei Nie, Yan Zhou, Changhui Li, Kai Gu, Ding Zhang,…& Xueyan Zhang (2021) Comutations in DDR Pathways Predict Atezolizumab Response in Non-Small Cell Lung Cancer Patients, Front. Immunol. 12:708558. doi: 10.3389/fimmu.2021.708558